BMS Nivolumab - Search News

Opdualag, Phase III and BMS

BMS study of Opdualag in adjuvant melanoma ends in failure

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 study, which enrolled people with stage III-IV melanoma that had been completely surgically removed.

BioSpace · 23h

BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

GlobalData on MSN · 23h

BMJ’s Phase III Opdualag study fails to meet endpoints

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Seeking Alpha on MSN · 1d

Bristol-Myers' Opdualag fails Phase 3 melanoma study

Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing Opdualag,

Monthly Prescribing Reference19h

Nivolumab/Relatlimab Combo Fails to Meet RFS Endpoint in Melanoma Trial

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

The Pharma Letter20h

Bristol Myers’ Phase III Opdualag trial misses goal

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatl ...

PMLiVE11d

BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...

Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

precisionmedicineonline8d

Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

PMLiVE9d

BMS receives CHMP recommendation for Breyanzi in follicular lymphoma

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD19-directed CAR T cell therapy, which is already approved in the EU for certain lymphomas, be authorised to treat ...

Targeted Oncology1d

Post–PD-1 Data in Melanoma Offers Insight into IO Approaches

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Cancer Therapy Advisor1d

Adjuvant Nivolumab Prolongs DFS, OS in MIBC

Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results